However she knew the object had changed in position, she knew the size of the cube, and she could correctly judge the distance of the cube in relation to other nearby objects. Inner and outer visual fields
Detection of movement in the inner and outer visual fields was tested. Within her inner visual field, LM could detect some motion, with horizontal motion more easily distinguished than vertical motion. In her peripheral visual field, the patient was never able to detect any direction of movement. LMs ability to judge velocities was also tested. LM underestimated velocities over 12 deg/s. Motion aftereffect and Phi phenomenon
Motion aftereffect of vertical stripes moving in a horizontal direction and a rotating spiral were tested. She was able to detect motion in both patterns, but reported motion aftereffect in only 3 of the 10 trials for the stripes, and no effect for the rotating spiral. She also never reported any impression of motion in depth of the spiral. In Phi phenomenon two circular spots of light appear alternating. It appears that the spot moves from one location to the other. Under no combination of conditions did the patient report any apparent movement. She always reported two independent light spots. Visually guided pursuit eye and finger movements
LM was to follow the path of a wire mounted onto a board with her right index finger. The test was performed under purely tactile (blindfolded), purely visual (glass over the board), or tactile-visual condition.
DTaP-IPV vaccine is a combination vaccine whose full generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine (IPV).It is also known as DTaP/IPV, dTaP/IPV, DTPa-IPV, or DPT-IPV. It protects against the infectious diseases diphtheria, tetanus, pertussis, and poliomyelitis.Branded formulations marketed in the USA are Kinrix from GlaxoSmithKline and Quadracel from Sanofi Pasteur.Repevax is available in the UK.Within Japan, the formulation is called  四種混合（shishukongou - "mixture of 4"). Astellas markets it under the クアトロバック (Quattro-back) formulation, while another is available from Mitsubishi Tanabe Pharma named テトラビック (Tetrabic). A previous product by Takeda Pharmaceutical Company has been withdrawn by the company. == References ==